Related news from
Mon, 22 Apr 2024 12:05:00 +0000	Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024 GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full year 2024. Conference Call InformationParticipants can access the conference call live via webcast. To participate via telephone, please register in advance at this
Wed, 17 Apr 2024 14:44:48 +0000	Institutional owners may take dramatic actions as Emergent BioSolutions Inc.'s (NYSE:EBS) recent 16% drop adds to one-year losses Key Insights Significantly high institutional ownership implies Emergent BioSolutions' stock price is sensitive to...
Mon, 01 Apr 2024 12:00:00 +0000	Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of DirectorsWARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company’s Board of Direct
Thu, 28 Mar 2024 12:15:00 +0000	Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with NARCAN® Nasal Spray and build on its longstanding efforts with public interest entities across the country Hundreds of thousands of NARCAN® Nasal Spray cartons are available in over 32,000 retail locations in the U.S., and Emergent is working to increase reach into workplaces, businesses and other locationsApproximately 22 million doses of NARCAN®
Mon, 25 Mar 2024 12:05:00 +0000	Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed “No Action Indicated” or NAI status classification for the company's Baltimore Bayview manufacturing facility. Based on this outcome, the Baltimore Bayview facility is considered to be in an acceptable state of compliance with regard to current good manufacturing practices (cGMP). “Quality and compliance excellence remains a top priori
Thu, 07 Mar 2024 18:58:29 +0000	Emergent BioSolutions Inc (EBS) Reports Mixed Fourth Quarter and Full Year 2023 Financial Results Net Loss Narrows in Q4; Full Year Revenues Hit Guidance Mid-Point
Thu, 07 Mar 2024 17:34:00 +0000	Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales Emergent (EBS) reports mixed earnings for fourth-quarter 2023. The company signs a forbearance agreement with its lenders, effective till April 2023-end.
Thu, 07 Mar 2024 15:33:05 +0000	Emergent BioSolutions Inc. (NYSE:EBS) Q4 2023 Earnings Call Transcript Emergent BioSolutions Inc. (NYSE:EBS) Q4 2023 Earnings Call Transcript March 6, 2024 Emergent BioSolutions Inc. misses on earnings expectations. Reported EPS is $-0.77 EPS, expectations were $-0.33. Emergent BioSolutions Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, […]
Thu, 07 Mar 2024 12:35:08 +0000	Q4 2023 Emergent BioSolutions Inc Earnings Call Q4 2023 Emergent BioSolutions Inc Earnings Call
Thu, 07 Mar 2024 04:30:14 +0000	Emergent BioSolutions (EBS) Q4 2023 Earnings Call Transcript EBS earnings call for the period ending December 31, 2023.
Wed, 06 Mar 2024 22:55:04 +0000	Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -133.33% and 11.70%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Wed, 06 Mar 2024 21:31:00 +0000	Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results Fourth Quarter 2023 Total Revenues of $277 million, which aligned our Full Year to the mid-point of guidanceFull Year 2023 Total Revenues of $1.05 billion, which was the mid-point of guidanceFourth Quarter 2023 Net Loss of $50 million and Adjusted EBITDA of $3 millionIssues Q1 2024 and FY 2024 guidance GAITHERSBURG, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2023. "Emergent has a long
Thu, 29 Feb 2024 12:00:00 +0000	Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024 GAITHERSBURG, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2023. Emergent’s newly appointed president and CEO, Joseph C. Papa, will provide remarks. Conference Call InformationParticipants can access the conference call live via webcast from the Investors page of Emergent’s website. To participate via telephone, pl
Wed, 21 Feb 2024 12:35:32 +0000	UPDATE 2-Emergent appoints former Bausch + Lomb CEO to head company Emergent BioSolutions said on Wednesday it has named former Bausch + Lomb CEO Joseph Papa to the top job as the company, which makes the opioid overdose reversal drug Narcan, aims to return to revenue growth. Shares of Emergent rose more than 10% before the bell. Papa has 35 years of experience in the healthcare industry.
Wed, 21 Feb 2024 12:00:00 +0000	Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company’s debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood
Tue, 13 Feb 2024 09:45:00 +0000	Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock? Repare Therapeutics Inc. (RPTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Wed, 17 Jan 2024 16:55:43 +0000	Emergent extends shelf life of opioid overdose reversal drug Narcan Emergent BioSolutions has extended shelf life of Narcan, its over-the-counter nasal spray to reverse opioid overdose, to four years from three, the U.S. health regulator said on Wednesday. The shelf life of Narcan 4 mg nasal spray was extended to three years from two years in 2020. Last year, the U.S. Food and Drug Administration approved the nasal spray as the first naloxone-based drug to be sold without a prescription amid the government's overall push to curb drug overdose-related deaths in the United States.
Fri, 12 Jan 2024 19:20:00 +0000	Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.
Thu, 11 Jan 2024 13:00:00 +0000	Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense GAITHERSBURG, Md., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has secured an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract with a maximum value up to $235.8 million to supply BioThrax® (Anthrax Vaccine Adsorbed) for use by all branches of the U.S. military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease. The new contract with the U.S. Department of Defense (DoD) and led by the Joint Program Executive Office for Ch
Tue, 09 Jan 2024 12:30:00 +0000	Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024 GAITHERSBURG, Md., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a global company providing solutions that address public health threats and brings lifesaving, life-extending products to market, today announced that Haywood Miller, Interim Chief Executive Officer and Rich Lindahl, Chief Financial Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m. PT. The audio link for Emergent's session may be accessed he